Europe Approves Nivolumab for Hodgkin Lymphoma Europe Approves Nivolumab for Hodgkin Lymphoma

The immunotherapy becomes the first PD-1 inhibitor approved for a hematologic malignancy in the European Union.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news